Sfoglia per Autore  

Opzioni
Mostrati risultati da 1 a 20 di 130
Titolo Tipologia Data di pubblicazione Autori File
Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution 01 - Articolo su rivista 2026 Malighetti, FedericaVilla, MatteoCrippa, ValentinaAroldi, AndreaCavalca, FabrizioGraudenzi, AlexBorin, Lorenza MariaZappaterra, AriannaManghisi, BeatriceMologni, LucaPiazza, RoccoGambacorti-Passerini, CarloRamazzotti, Daniele +
Palbociclib targets β-catenin for degradation and synergizes with KRAS or ERK5 inhibition in colorectal cancer preclinical models 01 - Articolo su rivista 2026 Villa, MatteoMalighetti, FedericaVilla, Alberto MariaCordani, NicolettaAroldi, AndreaRamazzotti, DanieleMologni, Luca +
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer 02 - Intervento a convegno 2025 Fontana, DMologni, L +
α-Triazolylboronic Acids: A Novel Scaffold to Target FLT3 in AML 01 - Articolo su rivista 2025 Mologni L.Crippa V. +
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 01 - Articolo su rivista 2025 Malighetti, FedericaVilla, MatteoVilla, Alberto MariaPelucchi, SaraAroldi, AndreaCortinovis, Diego LuigiCazzaniga, Marina ElenaMologni, LucaRamazzotti, DanieleCordani, Nicoletta +
A Novel Allosteric Inhibitor Targeting IMPDH at Y233 Overcomes Resistance to Tyrosine Kinase Inhibitors in Lymphoma 01 - Articolo su rivista 2025 Mologni L. +
Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer 01 - Articolo su rivista 2025 Crippa, ValentinaCordani, NicolettaVilla, Alberto MariaMalighetti, FedericaVilla, MatteoAroldi, AndreaPiazza, RoccoCortinovis, DiegoMologni, LucaRamazzotti, Daniele +
Comprehensive analysis of mutational processes across 20 000 adult and pediatric tumors 01 - Articolo su rivista 2025 Villa, MatteoMalighetti, FedericaVilla, Alberto MariaCordani, NicolettaAroldi, AndreaAntoniotti, MarcoGraudenzi, AlexPiazza, RoccoMologni, LucaRamazzotti, Daniele +
Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers 01 - Articolo su rivista 2025 Villa, MatteoCazzaniga, GiorgioBolognesi, MaddalenaMalighetti, FedericaCrippa, ValentinaAroldi, AndreaPagni, FabioPiazza, RoccoMologni, LucaRamazzotti, Daniele +
Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0) 99 - Altro 2025 Crippa V.Cordani N.Villa A. M.Malighetti F.Villa M.Aroldi A.Piazza R.Cortinovis D.Mologni L.Ramazzotti D. +
Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype 01 - Articolo su rivista 2025 Civettini, IvanZappaterra, AriannaCorti, PaolaAroldi, AndreaBiondi, AndreaCavalca, FabrizioCrippa, ValentinaCrosti, FrancescaFerrari, Giulia MariaMalighetti, FedericaMologni, LucaPiperno, AlbertoRamazzotti, DanieleScollo, ChiaraGambacorti-Passerini, Carlo +
An in silico evaluation of lorlatinib as a potential therapy for novel amino acid substitutions in the tyrosine kinase domain of the ALK protein associated with cancer 01 - Articolo su rivista 2025 Fontana D.Mologni L. +
Discovery of selective, metabolically stable pyrazole-based FLT3 inhibitors for the treatment of acute myeloid leukemia 01 - Articolo su rivista 2025 Crippa V.Mologni L. +
Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer 01 - Articolo su rivista 2025 Fontana D.Mologni L. +
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 02 - Intervento a convegno 2024 Fontana DMalighetti FVilla MZambon AGambacorti-Passerini CMologni L.
Behavior of the anti-apoptotic BCL-2 protein in non-small-cell lung cancer cell models in response to treatments with ALK inhibitors and its potential dual BCL2-ALK inhibition 01 - Articolo su rivista 2024 Fontana D.Mologni L. +
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 01 - Articolo su rivista 2024 Villa, MatteoMalighetti, FedericaSharma, Geeta G.Manfroni, ChiaraFontana, DilettaCordani, NicolettaMeneveri, RaffaellaPiazza, RoccoPagni, FabioCortinovis, DiegoMologni, Luca +
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis Mimicking Triple Negative Myelofibrosis 02 - Intervento a convegno 2024 D. FontanaI. CrespiaticoC. MastiniD. D’AlibertiM. MauriCM. MercadoS. SpinelliV. CrippaE. InzoliB. ManghisiI. CivettiniD. RamazzottiV. SangiorgioM. GengottiV. BrambillaA. AroldiC. BaroneR. OrsenigoA. CorsiM. SerafiniG. CazzanigaF. PagniE. AzzoniA. SessaC. Gambacorti-PasseriniEM. ElliL. MologniRocco Piazza. +
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 01 - Articolo su rivista 2024 Crespiatico I.Mastini C.D'Aliberti D.Mauri M.Mercado C. M.Fontana D.Spinelli S.Crippa V.Inzoli E.Manghisi B.Civettini I.Ramazzotti D.Sangiorgio V.Brambilla V.Aroldi A.Barone C.Orsenigo R.Serafini M.Mottadelli F.Cazzaniga G.Pagni F.Azzoni E.Gambacorti Passerini C.Elli E. M.Mologni L.Piazza R. +
Abstract 987: Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 02 - Intervento a convegno 2024 Malighetti, FedericaVilla, MatteoSharma, GeetaManfroni, ChiaraFontana, DilettaCordani, NicolettaMeneveri, RaffaellaPiazza, RoccoPagni, FabioCortinovis, DiegoMologni, Luca +
Mostrati risultati da 1 a 20 di 130
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile